Release Date: April 30, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you explain why Align Technology's business is performing well despite a decline in consumer sentiment? A: Joseph Hogan, President and CEO, noted that the company saw strong volume growth across North America, APAC, and Europe. The introduction of the Lumina scanner with restorative capability provided additional momentum. Growth was observed across product lines and regions, including both teen and adult segments, indicating a broad-based demand.
Q: How is Align Technology planning to mitigate the impact of tariffs? A: Joseph Hogan, President and CEO, stated that Align is well-positioned with its global supply chain. The company manufactures in China for the Chinese market and in Mexico for the U.S. market, which helps mitigate tariff impacts. Align is also prepared to address any issues with iTero shipments from Israel.
Q: What can investors expect from the upcoming Investor Day? A: Joseph Hogan, President and CEO, mentioned that the Investor Day will provide a comprehensive overview of Align's portfolio, demand outlook, and positioning from both a technology and commercial standpoint. The company plans to share developments since the last meeting and its future strategy.
Q: Can you provide more details on the ASP (Average Selling Price) dynamics and expectations? A: John Morici, CFO, explained that the ASP decline was primarily due to unfavorable foreign exchange and a shift to lower-priced products. However, the introduction of higher-priced products like the Mandibular Advancement with Occlusal Blocks could help stabilize ASPs. The company is also considering adjustments based on VAT rulings in the UK.
Q: How is Align Technology addressing financing challenges for consumers and providers? A: John Morici, CFO, highlighted that Align has partnered with HFD to offer better financing options, helping consumers manage costs. The company also provides favorable payment terms to providers, allowing them to extend financing to patients, which supports practice growth and Invisalign adoption.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。